irinotecan has been researched along with xr5944 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blackman, RK; Bulawa, CE; Charlton, P; Connolly, K; Fleming, JA; McClendon, AK; Osheroff, N; Reimer, C; Rudolph-Owen, LA; Sappal, DS; Thoroddsen, V | 1 |
| Brown, JL; Charlton, PA; Freathy, C; Harris, SM; Mistry, P | 1 |
2 other study(ies) available for irinotecan and xr5944
| Article | Year |
|---|---|
Biological characterization of MLN944: a potent DNA binding agent.
Topics: Animals; Antigens, Neoplasm; Camptothecin; Catalysis; Cell Cycle; Cell Line, Tumor; Cluster Analysis; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; G1 Phase; G2 Phase; Gene Expression Profiling; HCT116 Cells; Humans; Intercalating Agents; Irinotecan; Male; Mice; Mice, Nude; Mitosis; Mutation; Neoplasms, Experimental; Phenazines; Transplantation, Heterologous; Xenograft Model Antitumor Assays; Yeasts | 2004 |
Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Phenazines; Transplantation, Heterologous | 2005 |